Emmanuel Lugina Lugina

Dr. Emmanuel Lugina Lugina

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
SKSalama Iddy Khamis
Salama Iddy Khamis
AMAlita S. Mrema
Alita S. Mrema
JKJohnson Katanga
Johnson Katanga
ELEmmanuel Lugina Lugina
Emmanuel Lugina Lugina
PURPOSE: In Tanzania, cancer of cervix is the most commonly diagnosed cancer and is the leading cause of cancer-related deaths. There are very little data about survival of patients with cervical cancer after treatment in Tanzania. The aims of this study were to determine 5-year overall survival (OS) rate and its predictors among patients with cervical cancer treated at Ocean Road Cancer Institute (ORCI) from January to December 2012. MATERIALS AND METHODS: This was retrospective study done at ORCI by reviewing medical charts of 202 patients with cervical cancer treated at ORCI from January to December 2012. A structured questionnaire was used to extract information about characteristics of the respondents. Survival curves were estimated by using Kaplan-Meir analysis and were compared by using log-rank test. RESULTS: The 5-year OS rate was 26%. The mean and median survival times were 33.9 and 19 months, respectively. Factors that were positively associated with 5-year OS rate include the hemoglobin level more than 9 g/dL at presentation, early International Federation of Gynecology and Obstetrics stage at presentation, high dose of radiotherapy, and use of concurrent chemoradiotherapy. Histology type and HIV status were not associated with survival. CONCLUSION: The 5-year overall survival rate was 26%. Predictors of OS were hemoglobin level, stage at presentation, radiotherapy dose, and the use of concurrent chemoradiotherapy.

1 August 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAlita Mrema
Alita Mrema
MNMamsau Ngoma
Mamsau Ngoma
ELEmmanuel Lugina Lugina
Emmanuel Lugina Lugina
AKAtukuzwe Kahakwa
Atukuzwe Kahakwa
CMChacha Josiah Mwita
Chacha Josiah Mwita
JMJulius Mwaiselage
Julius Mwaiselage
Background: Cervical cancer (CC) is the leading cancer among women in Tanzania, especially among those between the ages of 15 and 44. The prevalence of high-risk Human papillomavirus (HR-HPV)-16/18 women in the general population at any given time is 3.3%. HR-HPVs 16 or 18 are the primary cause of CC. The distribution of HPV genotypes among women with CC according to HIV status is unknown in Tanzania. This study aimed to determine the HPV genotype distribution according to HIV status among women with CC in Tanzania. Methods: This cross-sectional study was done at Ocean Road Cancer Institute (ORCI) in Tanzania among women with histologically confirmed CC. HIV serology testing was performed. Biopsy was taken from cervical lesions, and DNA was extracted. HPV DNA was amplified by using a previously validated multiplex HPV PCR assay targeting 14 high-risk HPV genotypes (16,18,30,31,33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) and two low‐risk HPV genotypes (6 and 11). Continuous variables were compared using either a student t-test or the Mann-Whitney U test. Fisher’s exact test was employed to compare discrete variables. A P-value less than 0.05 was considered statistically significant. Results: We included 100 women with CC. The prevalence of HIV infection in this study was 42%. The prevalence of any HPV infection was 94%, ranging from 1–3 genotypes per woman. HPV. The median age for women living with HIV (WLWH) with CC patients was 45 years (IQR, 31–60), while the median age for HIV-uninfected women with CC patients was 57 years (IQR, 30–78). (p = 0.0001). WLWH and HIV-uninfected women had similar HPV prevalence, except for HPV 35, which was more common in WLWH. There was a trend of high prevalence of HPV 52 and HPV 58 in WLHH compared to HIV-uninfected women, but this difference was not statistically significant. The prevalence of HPV 16 and/or 18 infection in the entire sample was 85%. The combined prevalence of HPV 16 and/or 18 was 76% WLWH and 91% amongst HIV-uninfected women (p = 0.036).The majority of women (77.9%) had single-genotype HPV infection. There was no difference in the distribution of multiple or single HPV genotypes infection by HIV status (p = 0.25). Conclusion: In this study, HIV positive women with CC presented at a significantly younger age (45 years) compared to the HIV-negative women (57 years). The prevalence of high-risk HPV is high among women with CC in Tanzania. Distribution of most high-risk HPV genotypes among women with CC was not significantly influenced by HIV status except for HPV 35, which appeared to be more in HIV positive women compared to HIV-negative women. While the majority of the high-risk HPV infections were with single HPV genotypes, the prevalence of multiple high-risk HPV infections was at 22%, with no significant difference between the two HIV statuses. A vaccination program that aptly targets HPV 16 and 18 could prevent up to 85% of CC cases in Tanzania, regardless of HIV. Keywords: Human papillomavirus, cervical cancer, HIV, Tanzania.

11 November 2025 in The Oncologist
Verified
Journal Article
Open access
EREulade Rugengamanzi
Eulade Rugengamanzi
NDNazima Dharsee
Nazima Dharsee
ELEmmanuel Lugina Lugina
Emmanuel Lugina Lugina
JKJesse Jonathan Kashabano
Jesse Jonathan Kashabano
GMGad Murenzi
Gad Murenzi
ALAmie Y Lee
Amie Y Lee
Purpose: Breast cancer is a heterogeneous disease with a wide spectrum of subtypes, each with distinct biological features. Data on tumor subtypes in East Africa are sparse despite the rising incidence of breast cancer in this region. We aimed to determine the prevalence of triple-negative breast cancer (TNBC) and to compare clinicopathological features, overall survival (OS), and factors affecting OS of patients with TNBC and non-TNBC in Tanzania. Methods: This retrospective nested case–control study included patients with histologically proven breast cancer treated at Ocean Road Cancer Institute (ORCI) in Tanzania from January 2018 to December 2019. Logistic regression was used to determine factors associated with TNBC, and Cox proportional hazards regression was used to determine the factors independently associated with overall survival. Results: TNBC constituted 23.3% of all breast cancer diagnoses. Patients in the TNBC group were younger (median age 46 vs 53 years, P < .001) and more often presented with stage IV disease (12% vs 4%, P = .001). Three-year OS was significantly lower in the TNBC group (36%) compared to the non-TNBC group (57%) (P = .004) and remained lower for the TNBC group across every tumor stage. Brain metastasis was higher in the TNBC group (34% vs 7%, P < .001). Factors associated with improved survival included shorter symptom duration (0.53 [0.36-0.78]), earlier stage (0.23 [0.12-0.46]), use of neoadjuvant chemotherapy (0.59 [0.40-0.86]), and surgery with clean margins (0.34 [0.19-0.60]). Conclusions: TNBC accounted for nearly a quarter of the breast cancers at ORCI. TNBC was associated with younger age, more aggressive clinicopathologic features, and worse survival. Efforts toward earlier diagnosis and optimized therapies will be critical to improving TNBC outcomes in Tanzania.

1 August 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
LZLemi Ndugumbi Zinga
Lemi Ndugumbi Zinga
QTQueen Godfrey Tarimo
Queen Godfrey Tarimo
KMKelvin Mbelekwa
Kelvin Mbelekwa
MNMamsau Twalib Ngoma
Mamsau Twalib Ngoma
ELEmmanuel Lugina Lugina
Emmanuel Lugina Lugina
PURPOSE: Human epidermal growth factor receptor 2 (HER2)–positive breast cancer (HER2+BC) is linked to poorer outcomes. Trastuzumab is the standard treatment, but its high cost limits access in resource-limited settings. This study evaluated the treatment patterns and survival outcomes of patients with HER2 BC in Tanzania. MATERIALS AND METHODS: A retrospective hospital-based study was conducted between January 2018 and May 2021 at two prominent public tertiary hospitals in Tanzania. The primary outcome was the 5-year overall survival (OS) rate. Independent variables included demographics, clinical characteristics, and treatment patterns. Survival analysis was conducted using the Kaplan-Meier method. The log-rank test was used in univariate analysis, whereas multivariate Cox regression was used in multivariate analysis. RESULTS: A total of 169 patients with nonmetastatic HER2+BC were included, with a median age of 50 years. Most patients were estrogen receptor–positive (50.3%) and diagnosed with stage III BC (58.6%). About 70.4% of patients received trastuzumab, whereas neoadjuvant chemotherapy was administered to 24.3%, and 95.9% underwent mastectomy. Trastuzumab was primarily used in the adjuvant setting rather than the neoadjuvant setting and was more accessible to patients with higher socioeconomic status. The 5-year OS was 65%, with a median survival of 72 months. Trastuzumab reduced the mortality risk by 74%. Extended therapy with trastuzumab benefited patients with hormone receptor–negative HER2+BC more than those who were hormone receptor–positive. Advanced-stage disease increased mortality risk, whereas postmenopausal status and nonsmoking were associated with lower mortality. A higher Eastern Cooperative Oncology Group score (>1) was associated with an increased mortality risk. CONCLUSION: Trastuzumab significantly improves OS in resource-limited settings, particularly in patients with hormone receptor–negative HER2+BC. There are disparities in access to trastuzumab in Tanzania.

1 September 2023 in JCO Global Oncology
Verified
Journal Article
Open access
AMAlita Steven Mrema
Alita Steven Mrema
MNMamsau Ngoma
Mamsau Ngoma
CJChacha Josiah
Chacha Josiah
ELEmmanuel Lugina Lugina
Emmanuel Lugina Lugina
NMNanzoke Mvungi
Nanzoke Mvungi
JMJulius Mwaiselage
Julius Mwaiselage
PURPOSE: Cervical cancer (CC) is the leading malignancy in Tanzania. Low-income countries are faced with double epidemics of HIV and CC. This study aimed to investigate how HIV and cancer stage at diagnosis affect early treatment outcomes among women with CC treated with concurrent chemoradiation in Tanzania in the highly active antiretroviral therapy era. MATERIALS AND METHODS: This was a prospective cohort study of patients newly diagnosed with CC at the Ocean Road Cancer Institute from November 2019 to January 2020. The tumor response was assessed using RECIST 3 months post-treatment. The tumor response was categorized as a complete or partial response according to the ultrasound and pelvic examination findings. The univariate and multivariate logistic regression explained the relationship between several covariates (age, stage, HIV status, equivalent dose in 2 Gy fractions, chemotherapy cycles, and treatment time) and treatment response. RESULTS: A total of 102 patients with CC were included in this study at baseline. After adjusting for other covariates, only completion of treatment within 56 days (odds ratio [OR], 9.23; 95% CI, 1.53 to 55.85; P = .016) and receiving at least three cycles of cisplatin (OR, 5.6; 95% CI, 1.47 to 21.34; P = .012) were significantly associated with complete tumor response. HIV status was not significantly associated with complete tumor response (OR, 1.534; 95% CI, 0.424 to 5.545; P = .5144). CONCLUSION: Early treatment response was independent of HIV status. With wide coverage of anitretroviral therapy, patients with HIV can receive radical treatment and have the same early outcomes as their HIV-negative counterparts.

9 November 2023 in The Breast
Verified
Journal Article
Open access
RERugengamanzi Eulade
Rugengamanzi Eulade
ELEmmanuel Lugina Lugina
Emmanuel Lugina Lugina
NDNazima Dharsee
Nazima Dharsee
ALAmie Lee
Amie Lee
RWRebecca Wong
Rebecca Wong
AMAchille Manirakiza
Achille Manirakiza